Viatris (NASDAQ:VTRS) received approval from Japan’s Ministry of Health, Labour and Welfare for WAKIX (pitolisant) to treat excessive daytime sleepiness associated with obstructive sleep apnea syndrome and narcolepsy.
Viatris (NASDAQ:VTRS) has officially commenced the global expansion of its cardiovascular portfolio with the launch of Inpefa (sotagliflozin) in the United Arab Emirates, marking the first commercial availability of the therapy outside the United States.
Viatris (NASDAQ:VTRS) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Effexor® SR (venlafaxine hydrochloride) sustained-release capsules for the treatment of adults with generalized anxiety disorder (GAD).
